EPISODE · Jun 21, 2024 · 4 MIN
05 - ASCO again...
from Novità per il mondo dell'Oncologia · host Paolo Pronzato, Genova
Altri importanti lavori presentati all’ASCO 2024 sono stati contemporaneamente pubblicati sul Journal of Clinical Oncology. In rete possiamo trovare anche tutti gli abstracts di ASCO 2024 e il “prezioso” ASCO Educational Book. Riferimenti bibliograficiAbstracts ASCO 2024ASCO Educational BookSolomon BJ, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol 2024: JCO2400581. doi: 10.1200/JCO.24.00581. Epub ahead of print. Paz-Ares LG, et al. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol 2024: JCO2400733. doi: 10.1200/JCO.24.00733. Epub ahead of print.
What this episode covers
Altri importanti lavori presentati all’ASCO 2024 sono stati contemporaneamente pubblicati sul Journal of Clinical Oncology. In rete possiamo trovare anche tutti gli abstracts di ASCO 2024 e il “prezioso” ASCO Educational Book. Riferimenti bibliograficiAbstracts ASCO 2024ASCO Educational BookSolomon BJ, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol 2024: JCO2400581. doi: 10.1200/JCO.24.00581. Epub ahead of print. Paz-Ares LG, et al. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol 2024: JCO2400733. doi: 10.1200/JCO.24.00733. Epub ahead of print.
NOW PLAYING
05 - ASCO again...
No transcript for this episode yet
Similar Episodes
Apr 19, 2023 ·38m
Jan 19, 2023 ·32m
Dec 27, 2022 ·33m
Nov 6, 2022 ·42m
Oct 24, 2022 ·34m
Oct 2, 2022 ·43m